22 January 2026 – bd-capital, the pan-European, operator led investment firm, is proud to announce that, alongside its partner shareholders, it has sold Symprove to Metagenics, a California-based leading global provider of nutritional supplements.
Symprove is the UK’s number 1 probiotic and the most recommended probiotic by healthcare practitioners, where its scientifically proven market-leading water-based formulation is changing the lives of people living with digestive illnesses and discomfort, and improving the health of the gut microbiome for the wider community.
bd-capital partnered with Symprove in 2020 and since then has been proud to help drive the growth of the business alongside its founder, Barry Smith, and its exceptional management team, led by CEO Will Bowler. Since bd-capital’s investment, the company has more than tripled in size, and helped hundreds of thousands of people live healthier lives.
bd-capital were keen to ensure that the next stage of Symprove’s growth was with a partner who would reinforce its scientific focus and allow the product to extend its international reach beyond the UK, Ireland and European markets in which it already operates. In Metagenics, bd-capital believes that Symprove has found the perfect partner for the next stage in its journey.
Metagenics is a US-based global provider of nutritional supplements and offers Symprove the opportunity to reach a global consumer and patient universe, with a focus on healthcare professional advocacy supported by outstanding product efficacy. The business is backed by Gryphon Investors, a US-based private investment firm.
Andy Dawson, co-Founder and Managing Partner of bd-capital commented;
“We are very proud of how much Symprove has evolved since our investment in 2020. Partnering with Barry, Will and the team at Symprove has been a joy, while the growth of the business means that more people are benefiting from the positive health impact of taking the product every day. I am excited to see how Symprove continues to grow under the stewardship of Metagenics and Gryphon – I am sure the next chapter of the Symprove story will be incredibly positive.”
Ryan Fagan, Deal Partner at Gryphon Investors commented;
“We are pleased to be adding Symprove to the Metagenics family. Metagenics has been a fantastic partnership for us since our investment in 2021, and we are excited to have the opportunity to bring in a new brand to expand the product range and geographical reach of the group. Symprove’s scientifically proven product and unique patented formulation fits perfectly into the Metagenics product family, while offering many new avenues to drive distribution and growth in the US and internationally. We look forward to partnering with Will and his management team as we move forward together.”
Will Bowler, CEO of Symprove commented;
“We are excited to be partnering with the team at Metagenics – a company with a similar mission, values, and approach to Symprove. From day one, Symprove has been focused on delivering “life changing” gut health to its customers and in becoming part of the Metagenics group, we now have potential to do this on a global scale and become the world’s leading gut health brand.”
Will and his management team will continue to lead the business from Symprove’s headquarters in Surrey, UK, and Barry Smith, the founder of Symprove, will continue to support the company as a brand ambassador.
In the transaction, bd-capital worked closely with its exclusive financial advisor Jefferies, and partnered with advisors from Stephenson Harwood, PwC, and OC&C. Gryphon’s advisors were Greenhill & Co., Spayne Lindsay & Co., Kirkland & Ellis, and KPMG.
